Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05700994 · ClinicalTrials.gov registry record · NA
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
A NA study of Methamphetamine Abuse, sponsored by Oregon Health and Science University.
- Active
- Registry status
- NA
- Development phase
- 1,283
- Enrollment target
- 2
- Study locations
NCT05700994: Active NA study of Methamphetamine Abuse, sponsored by Oregon Health and Science University.
NCT05700994 is a NA study of Methamphetamine Abuse that is active but no longer recruiting, run by Oregon Health and Science University. The registered enrollment target is 1,283 participants, above the 123-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (943% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05700994, a NA study of Methamphetamine Abuse, is active but no longer recruiting, sponsored by Oregon Health and Science University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,283 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main goal of this study is to tests the effect of incentivizing achievement of self-identified, personal harm reduction goals (Contingency management or CM) compared with standard of care (peer harm reduction service with incentives for peer visits) to increase the reach and effectiveness of methamphetamine (MA) harm reduction services.
Primary Outcome
Test the impact of incentives for achieving self-identified, personal harm reduction goals on the likelihood of overdose among people using methamphetamine at 6 months from enrollment identified through completed assessment.
Conditions Studied
Interventions
- BEHAVIORAL Peer Contingency Management
- BEHAVIORAL Standard of Care Contingency Management
Study Locations (2)
Oregon
- Comagine Health - Portland
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,283 participants |
| Start Date | 2023-11-13 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What the registry record for NCT05700994 still lists
NCT05700994 is an interventional study that assigns participants to a tested intervention. Its 1,283 participants enrollment target places it among the larger protocols in the corpus, above the 123-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (943% higher).
The record links to 1 condition, with Methamphetamine Abuse appearing as the primary indexed condition, and to 2 interventions - of which Peer Contingency Management is the first listed.
NCT05700994 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05700994 about?
NCT05700994 is a clinical study titled "Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)". The main goal of this study is to tests the effect of incentivizing achievement of self-identified, personal harm reduction goals (Contingency management or CM) compared with standard of care (peer harm reduction service with incentives for peer visits) to increase the reach and effectiveness of met...
What is the current status of trial NCT05700994?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,283 participants. The study started on 2023-11-13. Estimated completion is 2026-09-30.
What conditions does trial NCT05700994 study?
This clinical trial studies the following conditions: Methamphetamine Abuse.
What interventions are being tested in trial NCT05700994?
The interventions under investigation include: Peer Contingency Management (BEHAVIORAL), Standard of Care Contingency Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT05700994?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05700994 being conducted?
This trial has 2 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05700994's enrollment target sits among peer trials
1,283 1st of 15 higher than 15 of 15 other Methamphetamine Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
Theta Burst TMS for Treatment of Methamphetamine Use Disorder
RECRUITING · NA
-
rTMS for Craving in Methamphetamine Use Disorder
RECRUITING · NA
-
Mood and Decision-making in Methamphetamine Use Disorder
RECRUITING · NA
-
Contingency Management for Drug Use: Does Age Matter?
ACTIVE NOT RECRUITING · NA
-
Demonstration of a Digital Care Program for Methamphetamine Use Disorder
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI